Cargando…

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling

PURPOSE: Apatinib is an inhibitor of VEGFR2 (vascular endothelial growth factor receptor 2) that has attracted a great deal of attention due to its promotion of anticancer activity. In the present study, we investigated the therapeutic effects of apatinib against colorectal cancer (CRC) and examined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Xiaomin, Wei, Bin, Li, Lele, Chen, Xiaofeng, Yang, Jing, Li, Xiaofei, Jiang, Xiaozheng, Lv, Mu, Li, Mingyang, Lin, Yumeng, Xu, Qiang, Guo, Wenjie, Gu, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606303/ https://www.ncbi.nlm.nih.gov/pubmed/33154652 http://dx.doi.org/10.2147/OTT.S266549

Ejemplares similares

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway
por: Wei, Bin, et al.
Publicado: (2020)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal cancer
por: Zhong, Mengya, et al.
Publicado: (2020)

Apatinib inhibits tumor growth and angiogenesis in PNET models
por: Wu, Shan, et al.
Publicado: (2018)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway
por: Xia, Liang, et al.
Publicado: (2022)

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report
por: Hou, Zhenyu, et al.
Publicado: (2020)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation
por: Mu, Xianmin, et al.
Publicado: (2012)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Apatinib as an optional treatment in metastatic colorectal cancer
por: Li, Aiyi, et al.
Publicado: (2019)

VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes
por: Li, Guangxin, et al.
Publicado: (2018)

VEGFR1 signaling in retinal angiogenesis and microinflammation
por: Uemura, Akiyoshi, et al.
Publicado: (2021)

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
por: Liu, Kuisheng, et al.
Publicado: (2017)

Probiotic Yeast Inhibits VEGFR Signaling and Angiogenesis in Intestinal Inflammation
por: Chen, Xinhua, et al.
Publicado: (2013)

Tussilagone Suppresses Angiogenesis by Inhibiting the VEGFR2 Signaling Pathway
por: Li, Jia, et al.
Publicado: (2019)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis
por: D'Haene, Nicky, et al.
Publicado: (2013)

Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
por: Kühn, Clemens, et al.
Publicado: (2019)

Tetraspanin18 regulates angiogenesis through VEGFR2 and Notch pathways
por: Li, Grace X., et al.
Publicado: (2021)

FGA Controls VEGFA Secretion to Promote Angiogenesis by Activating the VEGFR2-FAK Signalling Pathway
por: Li, Hui, et al.
Publicado: (2022)

The suppressing effects of VEGF-mediated angiogenesis at different administration sequences of apatinib and transarterial embolization in vivo
por: Li, Nan, et al.
Publicado: (2020)

DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling
por: Huang, Shiu-Wen, et al.
Publicado: (2016)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Rutacecarpine Inhibits Angiogenesis by Targeting the VEGFR2 and VEGFR2-Mediated Akt/mTOR/p70s6k Signaling Pathway
por: Ji, Lijun, et al.
Publicado: (2018)

Accelerated Coronary Angiogenesis by Vegfr1-Knockout Endocardial Cells
por: Zhang, Zheng, et al.
Publicado: (2013)

Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2
por: Tu, Yingfeng, et al.
Publicado: (2015)

Methylenetetrahydrofolate reductase C677T polymorphism and colorectal cancer susceptibility: a meta-analysis
por: Xu, Lingyan, et al.
Publicado: (2017)

eIF3i activity is critical for endothelial cells in tumor induced angiogenesis through regulating VEGFR and ERK translation
por: Zhang, Yaguang, et al.
Publicado: (2017)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment
por: Xie, Junye, et al.
Publicado: (2023)

Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis
por: Genet, Gael, et al.
Publicado: (2019)

Rapamycin suppresses angiogenesis and lymphangiogenesis in melanoma by downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 expression
por: Wang, Min, et al.
Publicado: (2019)

Studies of the Efficacy of Low-Dose Apatinib Monotherapy as Third-Line Treatment in Patients with Metastatic Colorectal Cancer and Apatinib’s Novel Anticancer Effect by Inhibiting Tumor-Derived Exosome Secretion
por: Zhao, Lingying, et al.
Publicado: (2022)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis
por: Gong, Anan, et al.
Publicado: (2022)

Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
por: Li, Ling, et al.
Publicado: (2020)

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
por: Li, Ling, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_krdbra9cilfp7b6nf814md8l8i